Sign up for our newsletter
Get health tips, wellness advice, and more

Thanks for signing up!
You've been added to our list and will hear from us soon.

See all Healthline's newsletters »
Content created by Healthline and sponsored by our partners. For more details click here.
Content sponsored by our partners. More details »

This content is created by the Healthline editorial team and is funded by a third party sponsor. The content is objective, medically accurate, and adheres to Healthline's editorial standards and policies. The content is not directed, edited, approved, or otherwise influenced by the advertisers represented on this page, with exception of the potential recommendation of the broad topic area.

Read more about Healthline's advertising and sponsorship policy.

Primary Progressive MS

Primary-progressive MS (PPMS) is one of the rare types of multiple sclerosis, and only affects 10 percent of those with the disease. Unlike those with relapsing-remitting MS (RRMS), people with PPMS experience a steady deterioration of neurologic function. There are no acute relapses or remissions. Some of the most common symptoms include trouble with balance and coordination and difficulty walking.

The approved therapies for MS target inflammation in the central nervous system, which doesn’t help those with PPMS. Because of this, treatment is focused on relieving individual symptoms and maintaining a good quality of life. Fortunately, new research is in the works for developing a disease-modifying drug for PPMS patients.